Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database

Goji Kimura 1, Kaori Kadoyama 1, J.B. Brown 2, Tsutomu Nakamura 3, Ikuya Miki 3, Kohshi Nisiguchi 3,4, Toshiyuki Sakaeda 1,4, and Yasushi Okuno 2

1. Center for Integrative Education in Pharmacy and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
2. Department of Clinical System Onco-Informatics, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
3. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
4. Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan

Abstract

Objective: The reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 1997 to 2011 were reviewed to assess serious adverse events induced by the administration of antipsychotics to children.

Methods: Following pre-processing of FAERS data by elimination of duplicated records as well as adjustments to standardize drug names, reports involving haloperidol, olanzapine, quetiapine, clozapine, ziprasidone, risperidone, and aripiprazole were analyzed in children (age 0-12). Signals in the data that signified a drug-associated adverse event were detected via quantitative data mining algorithms. The algorithms applied to this study include the empirical Bayes geometric mean, the reporting odds ratio, the proportional reporting ratio, and the information component of a Bayesian confidence propagation neural network. Neuroleptic malignant syndrome (NMS), QT prolongation, leukopenia, and suicide attempt were focused on as serious adverse events.

Results: In regard to NMS, the signal scores for haloperidol and aripiprazole were greater than for other antipsychotics. Significant signals of the QT prolongation adverse event were detected only for ziprasidone and risperidone. With respect to leukopenia, the association with clozapine was noteworthy. In the case of suicide attempt, signals for haloperidol, olanzapine, quetiapine, risperidone, and aripiprazole were detected.

Conclusions: It was suggested that there is a level of diversity in the strength of the association between various first- and second-generation antipsychotics with associated serious adverse events, which possibly lead to fatal outcomes. We recommend that research be continued in order to gather a large variety and quantity of related information, and that both available and newly reported data be placed in the context of multiple medical viewpoints in order to lead to improved levels of care.

Key words: antipsychotics, children, serious adverse events, FAERS, data mining, pharmacovigilance

Introduction

Second-generation antipsychotic drugs (SGAs) are thought to provide different therapeutic outcomes from first-generation antipsychotic drugs (FGAs), due to their relatively low affinity for dopamine D2 receptors and affinities for other receptors. SGAs are believed to improve negative symptoms, depression...
and quality of life more than FGAs [1]. Medical doctors understand that improved efficacy for these problems is a great advantage of SGAs; however, little information is available concerning their superiority [1]. Weight gain, hyperprolactinemia, and extrapyramidal symptoms (EPS) are commonly found in patients treated with FGAs or SGAs [2-5]. Additionally, neuroleptic malignant syndrome (NMS), QT prolongation, leukopenia, and suicidal behavior are reported for both [2-5]; however again, we do not have a consensus on which is better. Additionally, in 2009, a meta-analysis was published to compare the safety and efficacy of FGAs and SGAs, in which 150 double-blind studies were included with 21,533 participants [1]. The analysis concluded that SGAs differed in many properties and were not a homogenous class, strongly suggesting the importance of detailed investigation of each drug [1].

Recently, the use of antipsychotics, especially SGAs, has been increasing in children. This is, in part, explained by their off-label uses, including those for Attention Deficit / Hyperactivity Disorder (ADHD) [6-8]. In the USA, the use of SGAs for children has been approved since 2006, and this has also contributed to the increase. The surveillance of adverse event reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) suggested that antipsychotics are included in the top 5 reported suspect therapeutic drug classes in children [9]. In this study, the FAERS database was used to assess the associations between 5 representative SGAs and adverse events in children. A FGA, haloperidol, and the recently developed aripiprazole were also subjected to the investigation, and we focused on 4 rare adverse events, including NMS, QT prolongation, leukopenia, and suicidal behavior. Data mining algorithms were used for the quantitative detection of signals [10-18], where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event.

Methods

Data sources

Input data for this study were taken from the public release of the FAERS database, covering the period from the fourth quarter of 1997 through the third quarter of 2011. The total number of reports used was 4,671,217. Besides those from manufactures, reports can be submitted from health care professionals and the public. The database’s data structure adheres to the international safety reporting guidance issued by the International Conference on Harmonisation ICH E2B. A data set consists of 7 data tables: report sources (RPSR), patient demographic and administrative information (DEMO), drug therapy start and end dates (THER), indications for use/diagnosis (INDI), drug/biologic information (DRUG), adverse events (REAC), and patient outcomes (OUTC). Preferred terms (PTs) in the Medical Dictionary for Regulatory Activities (MedDRA) serve as the terminology for registration of adverse events in REAC table. Here, version 16.1 of MedDRA was used.

Before data mining was executed, several pre-processing steps of FAERS were undertaken. First, duplicated reports, which appear with multiple CASE field values in the database, were filtered by applying the FDA’s recommendation of adopting the most recent CASE number. This processing step reduced the number of reports from 4,671,217 to 3,472,494, a 25.7% reduction. Next, in order to account for registration of arbitrary drug names including trade names and abbreviations, which is permissible within the FAERS system, drug names were mapped into unified generic names via text mining. As a part of the standardization process, GNU Aspell was applied to detect spelling errors. Additionally, records of side effects that are not registered as associated with the use of a pharmaceutical, such as foods, beverages, or other medical treatments including radiation therapy were eliminated. Similarly, adverse event records with ambiguous drug names such as generic “beta blockers” were filtered out. As a final filter, only records were retained in which demographic information indicated that children less than 12 years old were the recipients of treatment. After applying this pre-mining filter pipeline, the total number of reports used was 94,635. Consequently, a total of 1,098,811 co-occurrences were found in 94,635 reports, where a co-occurrence was a pair constituting a drug and a drug-associated adverse event.

Definition of adverse events

According to MedDRA version 16.1, NMS, QT prolongation, leukopenia, and suicide attempt are coded with preferred terms PT10029282, PT10014387, PT10024384, and PT10042464 with 7, 10, 5, and 5 lower level of terms (LLTs) assigned, respectively.

Signal Detection Data Mining

Once a collection of filtered adverse event records are assembled, a key question is how to weight and extract meaningful events as adverse event signals. To this end, a number of algorithms have been developed, where the common element of the algorithms is that signals are defined as those events reported with a greater frequency than can be expected, given an estimated expectation for reporting frequency derived from the drugs and ADRs (adverse drug reaction events) in the record collection to be
analyzed [14-18]. The algorithms used in this study include: (1) the proportional reporting ratio (PRR) [10] which is used by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK; (2) the reporting odds ratio (ROR) [11] in use at the Netherlands Pharmacovigilance Centre; (3) the information component (IC) criteria [12] employed by the World Health Organization (WHO); (4) and the empirical Bayes geometric mean (EBGM) [13] which is a part of FDA analytical methods.

The PRR, ROR, IC, and EBGM methods all employ the use of 2x2 confusion matrices of drug-event counts; that is, a drug and an event are placed on the rows and columns of a matrix, and the frequency of the four possible outcomes is tabulated. Where the algorithms then differ is that IC and EBGM use Bayesian reasoning, while the PRR and ROR methods take the frequentist approach to statistical inference. Readers are encouraged to consult the references of each method to obtain extended details.

Here, we summarize the ways in which each test uses its reasoning and formulation to “detect” a signal. First we consider the classical, frequentist statistical approaches. In the PRR method, a signal is detected if the number of co-occurrences is 3 or more, and additionally, if the PRR is 2 or more with an associated $\chi^2$ value of 4 or more [10]. Using ROR, when the lower bound of the 95% two-sided confidence interval exceeds 1, it is an indication of an ADR signal [11].

Next, we consider the Bayesian methods for signal detection. The IC algorithm performs signal detection via the IC025 metric, which is a lower bound of the 95% two-sides confidence interval of IC, with an ADR signal indicated by the IC025 value exceeding 0 [12]. For the EBGM method, a lower one-sided 95% confidence bound of the EBGM, termed the EB05 metric, is used; EB05 is greater than or equal to 2.0 results in an ADR signal [13].

Finally, we need a criterion to unite our use of the various signal detection methods. In this study, we elect for the most direct, simple strategy: an adverse event is drug-associated when at least 1 of the 4 algorithms meets its above criteria for signal detection.

## Results

The total number of drug and reported adverse event co-occurrences with haloperidol was 1,600, with 2,802 for olanzapine, 2,440 for quetiapine, 519 for clozapine, 623 for ziprasidone, 5,219 for risperidone, and 2,553 for aripiprazole, representing 0.146%, 0.255%, 0.222%, 0.047%, 0.056%, 0.475%, and 0.232% of all co-occurrences in children in the filtered data-base, respectively. In total, 181, 345, 313, 119, 139, 380, and 269 adverse events were extracted as antipsychotics-associated adverse events with 999, 1,644, 1,386, 310, 361, 3,104, and 1,530 co-occurrences with a signal detected, respectively.

The signals for NMS were detected with the 5 antipsychotics other than clozapine and ziprasidone, and signal scores for haloperidol and aripiprazole were greater than for other antipsychotics in Table 1. As for QT prolongation, signals were detected for only ziprasidone and risperidone, and signal scores suggested a stronger association for ziprasidone (Table 2). The signal scores for leukopenia are listed in Table 3. Although signals were detected for quetiapine, clozapine, and risperidone, the association with clozapine was noteworthy. Table 4 shows the signal scores for suicide attempt, and signals for 5 antipsychotics; haloperidol, olanzapine, quetiapine, risperidone, and aripiprazole, were detected.

### Table 1. Signal scores for antipsychotics-associated neuroleptic malignant syndrome.

| Antipsychotics | N  | PRR ($\chi^2$) | ROR (95% CI) | IC (95% CI) | EBGM (95% CI) |
|----------------|----|----------------|--------------|-------------|---------------|
| Haloperidol    | 8  | 26.92 (174.0)* | 27.98 (13.77, 42.18)* | 2.71 (1.72, 3.71)* | 22.97 (12.11)* |
| Olanzapine     | 3  | 5.74 (7.5)*    | 5.81 (1.86, 9.77)* | 1.21 (-0.31, 2.73) | 2.27 (0.83)    |
| Quetiapine     | 8  | 17.62 (109.2)* | 18.30 (9.02, 27.59)* | 2.55 (1.56, 3.54)* | 15.03 (6.97)*  |
| Clozapine      | N.A.|               |              |             |               |
| Ziprasidone    | N.A.|               |              |             |               |
| Risperidone    | 10 | 10.28 (75.0)*  | 10.76 (5.70, 15.83)* | 2.41 (1.52, 3.31)* | 8.15 (3.79)*   |
| Aripiprazole   | 14 | 29.54 (357.0)* | 31.64 (18.36, 44.92)* | 3.30 (2.53, 4.07)* | 26.82 (16.85)* |

N: the number of co-occurrences. N.A.: Not Available
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval (two-sided for ROR and IC, and one-sided for EBGM).

An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals.
Table 2. Signal scores for antipsychotics-associated QT prolongation.

| Antipsychotics | N   | PRR (χ²) | ROR (95% CI) | IC (95% CI) | EBGM (95% CI) |
|----------------|-----|----------|--------------|-------------|---------------|
| Haloperidol    | 2   | 1.41 (0.0) | 1.41 (0.33, 2.47) | 0.06 (-1.72, 1.84) | 0.97 (0.31) |
| Olanzapine     | 1   | 0.40 (0.4) | 0.40 (0.06, 0.75) | -1.19 (-3.46, 1.08) | 0.40 (0.09) |
| Quetiapine     | 3   | 1.39 (0.1) | 1.39 (0.45, 2.33) | 0.15 (-1.36, 1.66) | 1.05 (0.41) |
| Ziprasidone    | N.A.| 27.83 (533.3)* | 28.25 (16.86, 39.64)* | 3.23 (2.59, 4.05)* | 25.07 (16.02)* |
| Risperidone    | 9   | 1.95 (3.3) | 1.96 (1.02, 2.90)* | 0.76 (-1.16, 1.68) | 1.65 (0.94) |
| Aripiprazole   | 3   | 1.33 (0.1) | 1.33 (0.43, 2.20) | 0.11 (-1.40, 1.62) | 1.02 (0.39) |

N: the number of co-occurrences. N.A.: Not Available
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval (two-sided for ROR and IC, and one-sided for EBGM).

An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals.

Table 3. Signal scores for antipsychotics-associated leukopenia

| Antipsychotics | N   | PRR (χ²) | ROR (95% CI) | IC (95% CI) | EBGM (95% CI) |
|----------------|-----|----------|--------------|-------------|---------------|
| Haloperidol    | N.A.|          |              |             |               |
| Olanzapine     | 2   | 0.82 (0.0) | 0.83 (0.21, 1.45) | -0.44 (-2.22, 1.34) | 0.69 (0.22) |
| Quetiapine     | 11  | 5.25 (33.6)* | 5.30 (2.92, 7.68)* | 1.89 (1.05, 2.73)* | 3.77 (2.19)* |
| Clozapine      | 8   | 18.15 (111.3)* | 18.30 (9.07, 27.52)* | 2.56 (1.57, 3.54)* | 15.33 (7.65)* |
| Ziprasidone    | N.A.|          |              |             |               |
| Risperidone    | 9   | 2.00 (3.6) | 2.01 (1.04, 2.98)* | 0.79 (-0.13, 1.71) | 1.68 (0.96) |
| Aripiprazole   | 2   | 0.91 (0.0) | 0.91 (0.23, 1.59) | -0.35 (-2.13, 1.43) | 0.74 (0.24) |

N: the number of co-occurrences. N.A.: Not Available
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval (two-sided for ROR and IC, and one-sided for EBGM).

An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals.

Table 4. Signal scores for antipsychotic-associated suicide attempt.

| Antipsychotics | N   | PRR (χ²) | ROR (95% CI) | IC (95% CI) | EBGM (95% CI) |
|----------------|-----|----------|--------------|-------------|---------------|
| Haloperidol    | 5   | 9.36 (29.4)* | 9.47 (3.91, 15.03)* | 1.84 (0.63, 3.06)* | 4.69 (1.75) |
| Olanzapine     | 10  | 10.69 (78.3)* | 10.96 (5.84, 16.08)* | 2.44 (1.55, 3.32)* | 8.56 (3.97)* |
| Quetiapine     | 6   | 7.36 (26.9)* | 7.46 (3.33, 11.60)* | 1.84 (0.72, 2.96)* | 4.03 (1.79) |
| Clozapine      | N.A.|          |              |             |               |
| Ziprasidone    | 1   | 4.80 (0.4) | 4.81 (0.67, 8.94) | 0.34 (-1.94, 2.62) | 1.15 (0.25) |
| Risperidone    | 13  | 7.45 (66.5)* | 7.69 (4.41, 10.96)* | 2.50 (1.51, 3.08)* | 5.75 (3.24)* |
| Aripiprazole   | 4   | 4.68 (8.2)* | 4.72 (1.76, 7.69)* | 1.28 (-0.06, 2.62) | 2.36 (1.00) |

N: the number of co-occurrences. N.A.: Not Available
PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean. CI: the confidence interval (two-sided for ROR and IC, and one-sided for EBGM).

An asterisk (*) indicates a statistically significant association, i.e., the adverse events are detected as signals.

Discussion

According to some recent reports, number of prescriptions for antipsychotics among younger patients has been increasing [6-8]. Furthermore, the Guideline “Clinical Investigation of Medicinal Products in the Pediatric Population” [19], which was developed by the ICH expert working group, categorized “children” as 2 to 11 years. Therefore, in this study, we focused on children less than 12 years old.

NMS is a rare, but potentially fatal complication of treatment with antipsychotic medication and is characterized by the development of severe muscle rigidity and hyperthermia, first described by Delay et al. in 1968 [20]. In spite of the long period of time since the first description, to the best of our knowledge, there have been few reports concerning the association between SGAs and NMS in children. In our study, signals were detected for 5 antipsychotics, i.e., haloperidol, quetiapine, ziprasidone, risperidone, and aripiprazole (Table 1). Signal scores were higher for haloperidol and aripiprazole than for the other antipsychotics, suggesting that SGAs show lower susceptibility to NMS. The precise pathophysiology of NMS remains unknown. It has been suggested that NMS is the result of dopamine D2 receptor blockade [20-22], whereas, dopamine D2 receptor antagonism does not fully explain all of the signs and symptoms of NMS [22]. According to antipsychotic receptor-binding profiles, relative affinities for the dopamine D2 re-
Cephalic EMG: empirical Bayes geometric mean; FDA: Food and Drug Administration; FAERS: FDA Adverse Event Reporting System; FGAs: first-generation antipsychotic drugs; IC: information component; MedDRA: Medical Dictionary for Regulatory Activities; NMS: neuropsychiatric syndrome; PRR: proportional reporting ratio; PT: preferred term; ROR: reporting odds ratio; SGAs: second-generation antipsychotic drugs

Acknowledgements

This study was partially supported by the Funding Program for Next Generation World-Leading Researchers and JSPS KAKENHI Grant Number 25460209.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31-41.
2. Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013; 16: 1205-1218.
3. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995; 346: 950-952.
4. Gareri P, Fazio PD, Fazio SD, et al. Adverse effects of atypical antipsychotics in the elderly. A review. Drugs Aging. 2006; 23: 937-956.
5. Gentile S. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: A Comprehensive Systematic Review. Psychopharmacology. 2013; 23: 1087-1106.
6. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotics in the United States. 1995-2008. Pharmacoeconomics. 2011; 29: 177-184.
7. Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic Medication Prescribing Trends in Children and Adolescents. J Pediatr Health Care. 2012; 2: 139-145.
8. Rani F, Murray ML, Byrn PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2006; 121: 1002-1009.
9. Johano-Logan R, Weyth J, Chen M, et al. Pediatric drug surveillance and the Food and Drug Administration’s adverse event reporting system: an overview of reports. 2003-2007. Pharmacoeconomics Drug Saf. 2009; 18(1):24-27.
10. Evans SJ, Waller PC, Davis S. Use of Proportional Reporting Ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoeconomics Drug Saf. 2001; 10: 483-486.
11. Van Puikenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoeconomics Drug Saf. 2002; 11: 3-10.
12. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54:315-321.
13. Straitman A, Machao SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002; 25: 381-392.
14. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoeconomics Drug Saf. 2009; 18: 427-436.
15. Hauben M, Reich L. Drug-induced pancreatitis: lessons in data mining. Br J Clin Pharmacol. 2004; 58: 560-562.
16. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005; 28: 981-1007.
17. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007; 82: 157-166.
18. Haulen B, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009; 14: 343-357.
19. [Internet] Pharmaceuticals and Medicinal Devices Agency: Tokyo, Japan. GUIDELINE for Efficacy, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Clinical Investigation of Medicinal Products in the Pediatric Population. http://www.pmda.go.jp/ich/e/e11_00_12_15e.pdf
20. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: A review. J Child Adolesc Psychopharmacol. 2009; 19: 415-422.
21. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013; 27: 545-572.
22. Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012; 43: 906-913.
23. Ozeki Y, Fujii K, Kurimoto N, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34: 401-405.
24. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf. 2013; 36: 467-479.
25. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011; 108: 687-693.
26. Maher KN, Tan M, Tossell JW, et al. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013; 23: 110-116.
27. Schneider C, Corrigall R, Hayes D, et al. Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. J Child Adolesc Psychopharmacol. 2013; 23: 110-116.
28. Manfredi G, Solfanelli A, Dimitri G, et al. Risperidone-induced leucopenia: a case report and brief review of literature. Gen Hosp Psychiatry. 2013; 35: 381.e3-102.e6.
29. Ettain B, Roubaud L, Le Heuzey MF et al. A case of leukopenia in treatment with risperidone in an adolescent. Encephale. 2000; 26: 81-84.
30. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: Internal Suicide Prevention Trial. Arch Gen Psychiatry. 2003; 60: 82-91.
31. Tiinhonen J, Loonqvist J, Wahlbeck K, et al. 11-year Follow-Up of Mortality in Patients with Schizophrenia: A Population-Based Cohort Study (FIN11 Study). Lancet. 2009; 374: 620-627.
32. Crocq MA, Naber D, Lader MH, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with Sertindole or Risperidone. Eur Neuropsychopharmacol. 2010; 20: 829-838.
33. Haukka J, Tiinhonen J, Harkanen T, et al. Association between medication and Risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoeconomics Drug Saf. 2008; 17: 686-696.
34. [Internet] Pharmaceuticals and Medicinal Devices Agency: Tokyo, Japan. GUIDELINE for Efficacy, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, http://www.pmda.go.jp/ich/e/e11_00_12_15e.pdf